Quarry LP Buys 2,478 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Quarry LP grew its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 11,263.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,500 shares of the company’s stock after acquiring an additional 2,478 shares during the quarter. Quarry LP’s holdings in Neurocrine Biosciences were worth $288,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. 1832 Asset Management L.P. boosted its position in Neurocrine Biosciences by 1,370.7% during the 2nd quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company’s stock worth $74,507,000 after acquiring an additional 504,400 shares during the last quarter. Los Angeles Capital Management LLC boosted its holdings in shares of Neurocrine Biosciences by 639.6% in the 3rd quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock valued at $48,479,000 after buying an additional 363,863 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Neurocrine Biosciences by 23.0% in the 2nd quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock valued at $166,959,000 after buying an additional 228,444 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Neurocrine Biosciences by 9.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock valued at $339,790,000 after buying an additional 216,500 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Neurocrine Biosciences by 40.3% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 710,600 shares of the company’s stock valued at $97,828,000 after buying an additional 203,934 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Neurocrine Biosciences

In related news, insider Jude Onyia sold 2,331 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $126.29, for a total value of $294,381.99. Following the sale, the insider now directly owns 15,449 shares of the company’s stock, valued at $1,951,054.21. This trade represents a 13.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 4.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

NBIX has been the subject of several recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a report on Monday, September 16th. Raymond James reissued an “outperform” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Barclays dropped their price target on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. StockNews.com cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Finally, HC Wainwright restated a “buy” rating and issued a $190.00 price target on shares of Neurocrine Biosciences in a research note on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $163.91.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX opened at $126.42 on Friday. The stock’s fifty day moving average is $120.07 and its 200 day moving average is $131.19. The stock has a market capitalization of $12.80 billion, a P/E ratio of 33.89 and a beta of 0.34. Neurocrine Biosciences, Inc. has a 52 week low of $110.95 and a 52 week high of $157.98.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.